The Rizzo laboratory is incredibly grateful for the support of the NIH/NHLBI, the Parker B. Francis Foundation, and the University of Pittsburgh.
Current Funding:
Funding Agency: Parker B Francis Foundation
Title: Alveolar epithelial glycocalyx degradation causes surfactant dysfunction in ARDS
Role: Principal Investigator
Start Year: 2023
End Year: 2026
Funding Agency: NIH/NHLBI
Title: ARDS endotyping via analysis of glycocalyx fragments in exhaled breath
Role: Principal Investigator
Grant Number: L30HL159703
Start Year: 2022
End Year: 2026
Prior Funding:
Funding Agency: NIH/NHLBI
Title: Epithelial glycocalyx degradation mediates surfactant dysfunction in acute respiratory distress syndrome
Role: Principal Investigator
Grant Number: F32HL162230
Start Year: 2022
End Year: 2023
Funding Agency: Colorado Clinical and Translational Sciences Institute (CTSI)
Title: ARDS endotyping via analysis of glycocalyx fragments in exhaled breath
Role: Principal Investigator
Grant Number: CO-M-21-5
Start Year: 2021
End Year: 2022
Funding Agency: NIH/NHLBI
Title: Functional Characterization of ALI-associated MYLK SNPs
Role: Principal Investigator
Grant Number: F30HL121982
Start Year: 2014
End Year: 2017
Funding Agency: American Heart Association
Title: The role of Abl family kinases in acute respiratory distress syndrome
Role: Principal Investigator
Grant Number: 14PRE18860021
Start Year: 2012
End Year: 2015